EICHORCondition: Advanced Solid Tumor · Sponsor: Strand Therapeutics Inc.
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab.
This description comes directly from the study's public registry record.
Jason Luke, MD, Chief Medical Officer · 617-993-9271 · stx-003-study@strandtx.com
Always discuss trial participation with your own doctor first.
| HonorHealth Research Institute | Scottsdale, Arizona, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07751042